advanced-treatment-validation-technology-set-to-improve-cancer-treatment-results 
Electronic Health Reporter
JULY 20, 2022
The article Advanced Treatment-Validation Technology Set To Improve Cancer Treatment Results appeared first on electronichealthreporter.com. A recent study from the Journal of the American Medical Association reported that while the U.S.
Digital Health Global
DECEMBER 11, 2023
The annual meeting serves as a premier platform for the exchange of groundbreaking research and advancements in the field of hematology, bringing together healthcare professionals, researchers, and industry leaders from around the world. NASHVILLE, Tenn.–(BUSINESS
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
JULY 20, 2023
By Alison Darcy, PhD, Founder & President Woebot Health Today I’m delighted to say we have registered the first known IRB-approved study of its kind on clinicaltrials.gov – a trial that seeks to explore how a reduced set of large language model (LLM)-augmented Woebot features compares with the same features in Woebot as it is today.
Healthcare IT Today
DECEMBER 5, 2023
Every interaction generates a trail of breadcrumbs, including clinical notes, lab results, and patient messages. Every interaction generates a trail of breadcrumbs, including clinical notes, lab results, and patient messages. We are committed to solving the information problem in healthcare.
DrKumo Remote Patient Monitoring
FEBRUARY 29, 2024
In today’s rapidly evolving world, technology continues to reshape various industries, and healthcare is no exception. One of the most groundbreaking advancements in recent years is the integration of Artificial Intelligence (AI) in healthcare systems. during the period from 2023 to 2032.
Healthcare IT Today
JANUARY 8, 2024
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. There is a growing interest in the integration of safety services with technology, and this will continue into 2024.
Digital Health Today
AUGUST 7, 2019
DTx are also attractive for pharmaceuticals because they have the potential to treat diseases with no or limited current treatment, like IBS (Inflammatory Bowel Syndrome) and to address better comorbidities with a unique solution: 30% of patients with migraine also suffer from IBS for instance. They could even become the new biosimilar.
Expert insights. Personalized for you.
142 
Let's personalize your content